Craft

Advanced
Immunovant

Immunovant

Stock Price

$29.9

2024-10-29

Market Capitalization

$4.4 B

2024-10-29

Immunovant Summary

Company Summary

Overview
Immunovant is a biopharmaceutical company focused on autoimmune diseases. Its product IMVT-1401 is a human monoclonal antibody targeting the neonatal Fc receptor (FcRn) to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection.
Type
Public
Status
Active
Founded
2018
HQ
New York, NY, US | view all locations
Website
https://immunovant.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Table of Contents

Key People

  • Pete Salzmann

    Pete Salzmann, Chief Executive Officer, Director

    • Julia G. Butchko

      Julia G. Butchko, Chief Development & Technology Officer

      • Swami Nathan

        Swami Nathan, VP, Special Projects

        • Rod Saponjic

          Rod Saponjic, VP, Clinical Operations

          LocationsView all

          3 locations detected

          • New York, NY HQ

            United States

            320 W 37th St 6th floor

          • Durham, NC

            United States

            1000 Park Forty Plaza #210

          • Basel, BS

            Switzerland

            Viaduktstrasse 8

          Immunovant Financials

          Summary Financials

          Net income (Q3, 2026)
          ($110.6M)
          Cash (Q3, 2026)
          $994.5M

          Competitors and Similar Companies

          Compare competitors

          Footer menu

          Product

          Solutions

          Resources

          Company

          © Craft.co 2026
          Share price data provided by IEX